Avalo Therapeutics (NASDAQ:AVTX) stock rises as Cantor Fitzgerald launches coverage with an Overweight rating, highlighting its lead asset, AVTX-009. Read more here.

The firm will pick two lead agents targeting PSMA and CLDN18.2 later this year and a third STEAP1-targeting drug next year.

Since President Donald J. Trump took office, his unwavering commitment to revitalizing American industry has spurred trillions of dollars of ...